Online inquiry

IVTScrip™ mRNA-Anti-IL13, CDP7766(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5600MR)

This product GTTS-WQ5600MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets IL13 gene. The antibody can be applied in Asthma research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001354991.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3596
UniProt ID P35225
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL13, CDP7766(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ5600MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3433MR IVTScrip™ mRNA-Anti-HGF, AV-299(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA AV-299
GTTS-WQ12856MR IVTScrip™ mRNA-Anti-TLR2, OPN-305(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA OPN-305
GTTS-WQ10211MR IVTScrip™ mRNA-Anti-RHD, LFB-R593(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LFB-R593
GTTS-WQ14579MR IVTScrip™ mRNA-Anti-CD38, SAR-650984(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA SAR-650984
GTTS-WQ2822MR IVTScrip™ mRNA-Anti-NGF, AMG-403(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG-403
GTTS-WQ14MR IVTScrip™ mRNA-Anti-S, 2130(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 2130
GTTS-WQ6907MR IVTScrip™ mRNA-Anti-Alkaline phosphatase substitute, ENB-0040(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ENB-0040
GTTS-WQ2160MR IVTScrip™ mRNA-Anti-IL6, ALD-518(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ALD-518
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW